Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

157 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Role of c-Met as a Biomarker and Player in Innate and Acquired Resistance in Non-Small-Cell Lung Cancer: Two New Mutations Warrant Further Studies.
Van Der Steen N, Zwaenepoel K, Mazzaschi G, A Luirink R, P Geerke D, Op de Beeck K, Hermans C, Tiseo M, Van Schil P, Lardon F, Germonpré P, Rolfo C, Giovannetti E, J Peters G, Pauwels P. Van Der Steen N, et al. Among authors: germonpre p, p geerke d. Molecules. 2019 Dec 4;24(24):4443. doi: 10.3390/molecules24244443. Molecules. 2019. PMID: 31817278 Free PMC article.
A Multicenter Study to Assess EGFR Mutational Status in Plasma: Focus on an Optimized Workflow for Liquid Biopsy in a Clinical Setting.
Sorber L, Zwaenepoel K, De Winne K, Van Casteren K, Augustus E, Jacobs J, Zhang XH, Galdermans D, De Droogh E, Lefebure A, Morel AM, Saenen E, Bustin F, Demedts I, Himpe U, Pieters T, Germonpré P, Derijcke S, Deschepper K, Van Meerbeeck JP, Rolfo C, Pauwels P. Sorber L, et al. Among authors: germonpre p. Cancers (Basel). 2018 Aug 27;10(9):290. doi: 10.3390/cancers10090290. Cancers (Basel). 2018. PMID: 30150518 Free PMC article.
ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it.
Rolfo C, Passiglia F, Castiglia M, Raez LE, Germonpre P, Gil-Bazo I, Zwaenepoel K, De Wilde A, Bronte G, Russo A, Van Meerbeeck JP, Van Schil P, Pauwels P. Rolfo C, et al. Among authors: germonpre p. Transl Lung Cancer Res. 2014 Aug;3(4):250-61. doi: 10.3978/j.issn.2218-6751.2014.03.01. Transl Lung Cancer Res. 2014. PMID: 25806308 Free PMC article. Review.
Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study.
van Puijenbroek R, Bosquée L, Meert AP, Schallier D, Goeminne JC, Tits G, Collard P, Nackaerts K, Canon JL, Duplaquet F, Galdermans D, Germonpré P, Azerad MA, Vandenhoven G, De Greve J, Vansteenkiste J. van Puijenbroek R, et al. Among authors: germonpre p. Eur Respir J. 2007 Jan;29(1):128-33. doi: 10.1183/09031936.00050706. Epub 2006 Sep 27. Eur Respir J. 2007. PMID: 17005582 Free article.
Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer.
Gerber DE, Horn L, Boyer M, Sanborn R, Natale R, Palmero R, Bidoli P, Bondarenko I, Germonpre P, Ghizdavescu D, Kotsakis A, Lena H, Losonczy G, Park K, Su WC, Tang M, Lai J, Kallinteris NL, Shan JS, Reck M, Spigel DR. Gerber DE, et al. Among authors: germonpre p. Ann Oncol. 2018 Jul 1;29(7):1548-1553. doi: 10.1093/annonc/mdy177. Ann Oncol. 2018. PMID: 29767677 Free PMC article. Clinical Trial.
Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO).
Vansteenkiste J, Barlesi F, Waller CF, Bennouna J, Gridelli C, Goekkurt E, Verhoeven D, Szczesna A, Feurer M, Milanowski J, Germonpre P, Lena H, Atanackovic D, Krzakowski M, Hicking C, Straub J, Picard M, Schuette W, O'Byrne K. Vansteenkiste J, et al. Among authors: germonpre p. Ann Oncol. 2015 Aug;26(8):1734-40. doi: 10.1093/annonc/mdv219. Epub 2015 May 4. Ann Oncol. 2015. PMID: 25939894 Free article. Clinical Trial.
157 results